Skip to main content
NCBI home page
The Journal of Clinical Investigation logoLink to The Journal of Clinical Investigation
. 1978 Feb;61(2):314–319. doi: 10.1172/JCI108941

Inhibition of platelet prostaglandin synthetase by oral aspirin.

J W Burch, N Stanford, P W Majerus
PMCID: PMC372541  PMID: 413839

Abstract

Aspirin inhibits platelet function by permanently acetylating the cyclooxygenase that forms prostaglandins. We determined the sensitivity of platelets to aspirin in normal subjects by measuring [3H-acetyl]aspirin-susceptible cyclooxygenase in washed platelets obtained at various times after aspirin ingestion. A single 325-mg aspirin dose inactivated 89% of platelet cyclooxygenase. The inhibition persisted for 2 days suggesting that oral aspirin also inactivated megakaryocyte cyclooxygenase. Thereafter, active enzyme returned with a time-course reflecting platelet turnover (life-span 8.2+/-2 days). Single doses of 20-650 mg aspirin resulted in 34- greater than 95% inhibition after 24 h. Daily doses of 20-325 mg aspirin for brief periods produced 61- greater than 95% inactivation when measured 24 h after cessation of the drug. Platelet cyclooxygenase is more sensitive to inactivation by aspirin than enzyme in sheep seminal vesicles.

Full text

PDF
314

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Abrahamsen A. F. Platelet survival studies in man. With special reference to thrombosis and atherosclerosis. Scand J Haematol Suppl. 1968;3:1–53. [PubMed] [Google Scholar]
  2. Baenziger N. L., Dillender M. J., Majerus P. W. Cultured human skin fibroblasts and arterial cells produce a labile platelet-inhibitory prostaglandin. Biochem Biophys Res Commun. 1977 Sep 9;78(1):294–301. doi: 10.1016/0006-291x(77)91253-0. [DOI] [PubMed] [Google Scholar]
  3. Baenziger N. L., Majerus P. W. Isolation of human platelets and platelet surface membranes. Methods Enzymol. 1974;31:149–155. doi: 10.1016/0076-6879(74)31015-4. [DOI] [PubMed] [Google Scholar]
  4. Bunting S., Gryglewski R., Moncada S., Vane J. R. Arterial walls generate from prostaglandin endoperoxides a substance (prostaglandin X) which relaxes strips of mesenteric and coeliac ateries and inhibits platelet aggregation. Prostaglandins. 1976 Dec;12(6):897–913. doi: 10.1016/0090-6980(76)90125-8. [DOI] [PubMed] [Google Scholar]
  5. Collier J. G., Flower R. J. Effect of aspirin on human seminal prostaglandins. Lancet. 1971 Oct 16;2(7729):852–853. doi: 10.1016/s0140-6736(71)90225-x. [DOI] [PubMed] [Google Scholar]
  6. Corash L., Tan H., Gralnick H. R. Heterogeneity of human whole blood platelet subpopulations. I. Relationship between buoyant density, cell volume, and ultrastructure. Blood. 1977 Jan;49(1):71–87. [PubMed] [Google Scholar]
  7. Elwood P. C., Cochrane A. L., Burr M. L., Sweetnam P. M., Williams G., Welsby E., Hughes S. J., Renton R. A randomized controlled trial of acetyl salicylic acid in the secondary prevention of mortality from myocardial infarction. Br Med J. 1974 Mar 9;1(5905):436–440. doi: 10.1136/bmj.1.5905.436. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Gryglewski R. J., Bunting S., Moncada S., Flower R. J., Vane J. R. Arterial walls are protected against deposition of platelet thrombi by a substance (prostaglandin X) which they make from prostaglandin endoperoxides. Prostaglandins. 1976 Nov;12(5):685–713. doi: 10.1016/0090-6980(76)90047-2. [DOI] [PubMed] [Google Scholar]
  9. Hamberg M., Svensson J., Samuelsson B. Thromboxanes: a new group of biologically active compounds derived from prostaglandin endoperoxides. Proc Natl Acad Sci U S A. 1975 Aug;72(8):2994–2998. doi: 10.1073/pnas.72.8.2994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  10. Horton E. W., Jones R. L., Marr C. G. Effects of aspirin on prostaglandin and fructose levels in human semen. J Reprod Fertil. 1973 Jun;33(3):385–392. doi: 10.1530/jrf.0.0330385. [DOI] [PubMed] [Google Scholar]
  11. Jafari E., Saleem A., Shaikh B. S., Demers L. M. Effect of aspirin on prostaglandin synthesis by human platelets. Prostaglandins. 1976 Nov;12(5):829–835. doi: 10.1016/0090-6980(76)90056-3. [DOI] [PubMed] [Google Scholar]
  12. Kocsis J. J., Hernandovich J., Silver M. J., Smith J. B., Ingerman C. Duration of inhibition of platelet prostaglandin formation and aggregation by ingested aspirin or indomethacin. Prostaglandins. 1973 Feb;3(2):141–144. doi: 10.1016/0090-6980(73)90081-6. [DOI] [PubMed] [Google Scholar]
  13. LOWRY O. H., ROSEBROUGH N. J., FARR A. L., RANDALL R. J. Protein measurement with the Folin phenol reagent. J Biol Chem. 1951 Nov;193(1):265–275. [PubMed] [Google Scholar]
  14. Majerus P. W. Editorial: Why aspirin? Circulation. 1976 Sep;54(3):357–359. doi: 10.1161/01.cir.54.3.357. [DOI] [PubMed] [Google Scholar]
  15. Malmsten C., Hamberg M., Svensson J., Samuelsson B. Physiological role of an endoperoxide in human platelets: hemostatic defect due to platelet cyclo-oxygenase deficiency. Proc Natl Acad Sci U S A. 1975 Apr;72(4):1446–1450. doi: 10.1073/pnas.72.4.1446. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Mielke C. H., Jr, Kaneshiro M. M., Maher I. A., Weiner J. M., Rapaport S. I. The standardized normal Ivy bleeding time and its prolongation by aspirin. Blood. 1969 Aug;34(2):204–215. [PubMed] [Google Scholar]
  17. Moncada S., Gryglewski R. J., Bunting S., Vane J. R. A lipid peroxide inhibits the enzyme in blood vessel microsomes that generates from prostaglandin endoperoxides the substance (prostaglandin X) which prevents platelet aggregation. Prostaglandins. 1976 Nov;12(5):715–737. doi: 10.1016/0090-6980(76)90048-4. [DOI] [PubMed] [Google Scholar]
  18. Mustard J. F. The Gordon Wilson lecture: function of blood platelets and their role in thrombosis. Trans Am Clin Climatol Assoc. 1976;87:104–127. [PMC free article] [PubMed] [Google Scholar]
  19. O'Brien J. R. Effects of salicylates on human platelets. Lancet. 1968 Apr 13;1(7546):779–783. doi: 10.1016/s0140-6736(68)92228-9. [DOI] [PubMed] [Google Scholar]
  20. Patrono C., Ciabattoni G., Greco F., Grossi-Belloni D. Comparative evaluation of the inhibitory effects of aspirin-like drugs on prostaglandin production by human platelets and synovial tissue. Adv Prostaglandin Thromboxane Res. 1976;1:125–131. [PubMed] [Google Scholar]
  21. Ross R., Glomset J. A. The pathogenesis of atherosclerosis (second of two parts). N Engl J Med. 1976 Aug 19;295(8):420–425. doi: 10.1056/NEJM197608192950805. [DOI] [PubMed] [Google Scholar]
  22. Roth G. J., Majerus P. W. The mechanism of the effect of aspirin on human platelets. I. Acetylation of a particulate fraction protein. J Clin Invest. 1975 Sep;56(3):624–632. doi: 10.1172/JCI108132. [DOI] [PMC free article] [PubMed] [Google Scholar]
  23. Roth G. J., Stanford N., Majerus P. W. Acetylation of prostaglandin synthase by aspirin. Proc Natl Acad Sci U S A. 1975 Aug;72(8):3073–3076. doi: 10.1073/pnas.72.8.3073. [DOI] [PMC free article] [PubMed] [Google Scholar]
  24. Schwartz A. D. A method for demonstrating shortened platelet survival utilizing recovery from aspirin effect. J Pediatr. 1974 Mar;84(3):350–354. doi: 10.1016/s0022-3476(74)80715-8. [DOI] [PubMed] [Google Scholar]
  25. Shulman N. R., Watkins S. P., Jr, Itscoitz S. B., Students A. B. Evidence that the spleen retains the youngest and hemostatically most effective platelets. Trans Assoc Am Physicians. 1968;81:302–313. [PubMed] [Google Scholar]
  26. Smith J. B., Ingerman C., Silver M. J. Persistence of thromboxane A2-like material and platelet release-inducing activity in plasma. J Clin Invest. 1976 Nov;58(5):1119–1122. doi: 10.1172/JCI108564. [DOI] [PMC free article] [PubMed] [Google Scholar]
  27. Smith J. B., Willis A. L. Aspirin selectively inhibits prostaglandin production in human platelets. Nat New Biol. 1971 Jun 23;231(25):235–237. doi: 10.1038/newbio231235a0. [DOI] [PubMed] [Google Scholar]
  28. Stanford N., Roth G. J., Shen T. Y., Majerus P. W. Lack of covalent modification of prostaglandin synthetase (cyclo-oxygenase) by indomethacin. Prostaglandins. 1977 Apr;13(4):669–675. doi: 10.1016/0090-6980(77)90237-4. [DOI] [PubMed] [Google Scholar]
  29. Stuart M. J., Murphy S., Oski F. A. A simple nonradioisotope technic for the determination of platelet life-span. N Engl J Med. 1975 Jun 19;292(25):1310–1313. doi: 10.1056/NEJM197506192922502. [DOI] [PubMed] [Google Scholar]
  30. Tollefsen D. M., Feagler J. R., Majerus P. W. The binding of thrombin to the surface of human platelets. J Biol Chem. 1974 Apr 25;249(8):2646–2651. [PubMed] [Google Scholar]
  31. Verstraete M. Are agents affecting platelet functions clinically useful? Am J Med. 1976 Dec;61(6):897–914. doi: 10.1016/0002-9343(76)90414-9. [DOI] [PubMed] [Google Scholar]
  32. Wallach D. P., Daniels E. G. Properties of a novel preparation of prostaglandin synthetase from sheep seminal vesicles. Biochim Biophys Acta. 1971 May 4;231(3):445–457. doi: 10.1016/0005-2760(71)90112-3. [DOI] [PubMed] [Google Scholar]
  33. Weiss H. J., Aledort L. M., Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. J Clin Invest. 1968 Sep;47(9):2169–2180. doi: 10.1172/JCI105903. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Weiss H. J. Antiplatelet drugs-a new pharmacologic approach to the prevention of thrombosis. Am Heart J. 1976 Jul;92(1):86–102. doi: 10.1016/s0002-8703(76)80408-5. [DOI] [PubMed] [Google Scholar]

Articles from Journal of Clinical Investigation are provided here courtesy of American Society for Clinical Investigation

RESOURCES